

I. Epidemiological profile

Population	2013	%
Number of active foci	0	
Number of people living within active foci	0	0
Number of people living in malaria-free areas	21 300 000	100
Total	21 300 000	


Parasites and vectors			
Major plasmodium species: <i>P. falciparum</i> (0%), <i>P. vivax</i> (0%)			
Major anopheles species: <i>An. culicifacies</i> , <i>An. subpictus</i> , <i>An. annularis</i> , <i>An. varuna</i>			
Programme phase: Elimination			
Total confirmed cases, 2013:	95	Indigenous cases, 2013:	0
Total deaths, 2013:	0	Indigenous deaths, 2013:	0

II. Intervention policies and strategies





Intervention	Policies/strategies	Yes/No	Year adopted
ITN	ITNs/LLINs distributed free of charge	Yes	1992
	ITNs/LLINs distributed to all age groups	Yes	2004
IRS	IRS is recommended	Yes	1945
	DDT is authorized for IRS	No	-
Larval control	Use of larval control recommended	Yes	-
IPT	IPT used to prevent malaria during pregnancy	N/A	-
Diagnosis	Patients of all ages should receive diagnostic test	Yes	-
	Malaria diagnosis is free of charge in the public sector	Yes	1911
Treatment	ACT is free for all ages in public sector	-	-
	Artemisinin-based monotherapies withdrawn	-	-
	Single dose of primaquine is used as gametocidal medicine for <i>P. falciparum</i>	Yes	-
	Primaquine is used for radical treatment of <i>P. vivax</i>	Yes	-
	G6PD test is a requirement before treatment with primaquine	Yes	-
	Directly observed treatment with primaquine is undertaken	Yes	-
	System for monitoring of adverse reactions to antimalarials exists	Yes	-

Intervention	Policies/strategies	Yes/No	Year adopted				
Surveillance	ACD for case investigation (reactive)	Yes	-				
	ACD of febrile cases at community level (pro-active)	Yes	-				
	Mass screening is undertaken	Yes	-				
	Uncomplicated <i>P. falciparum</i> cases routinely admitted	Yes	2008				
	Uncomplicated <i>P. vivax</i> cases routinely admitted	No	-				
	Foci and case investigation undertaken	Yes	1958				
	Case reporting from private sector is mandatory	Yes	2008				
Antimalaria treatment policy			Year adopted				
First-line treatment of unconfirmed malaria		-	-				
First-line treatment of <i>P. falciparum</i>		AL+PQ	2008				
Treatment failure of <i>P. falciparum</i>		QN	1936				
Treatment of severe malaria		CQ+PQ(14d)	2008				
Treatment of <i>P. vivax</i>		AL (2nd & 3rd trimester); QN	-				
Dosage of primaquine for radical treatment of <i>P. vivax</i>		0.25 mg/kg (14 days)	-				
Therapeutic efficacy tests (clinical and parasitological failure, %)							
Medicine	Year	Min	Median	Max	Follow-up	No. of studies	Species
-	-	-	-	-	-	-	-



III. Financing



IV. Coverage



V. Impact



Impact: Achieved >75% decrease in case incidence in 2013